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ABSTRACT
Biologics have revolutionized the therapy of the
psoriatic disease spectrum. These new classes of
drugs also allow deeper insight into the
pathogenesis of the disease and highlight the
existence of distinct ‘‘molecular’’ disease
subgroups as evidenced by the spectrum of
clinical response seen. Molecules associated
with both the interleukin (IL)-17 and
interferon (IFN)c pathways have important
functions in psoriatic inflammation, and both
are targeted by drugs acting on the p40 subunit
shared by IL-12 and IL-23. These IL-12 family
members are upstream of pathways
characterized by the production of IFNc and
IL-17 related molecules, including IL-17, IL-22,
and CCL20. We here summarize the mode of
action and clinical studies of the p40 inhibitor
ustekinumab with focus on both psoriasis and
psoriatic arthritis.
Keywords: IL-12/IL-23 inhibition; Psoriasis;
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INTRODUCTION
The pathogenesis of the psoriatic disease
spectrum involves a plethora of cells and
mediators. Given the complexity of the skin
cytokine network, the cross regulation between
infiltrating leukocyte subsets, endothelial cells
and tissue resident mesenchymal and epithelial
cells as well as tissue resident immune cells
including innate leukocyte cell (ILC) subsets, it
seems surprising that disease symptoms are
responsive to a relatively wide array of
interventions. In particular, patients with
psoriasis respond to treatment interfering with
lymphocyte activation, the tumor necrosis
factor (TNF) pathway, agents blocking
interleukin (IL)-17 or the IL-12/23p40 subunit.
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The reason for different pathway blockage to
work therapeutically in psoriasis lies most
probably in their synergistic action which
ultimately drives psoriatic inflammation.
Synergistic activity regarding cell activation
and cytokine production has been highlighted
in a large number of studies mainly based on
in vitro work. Very potent ‘‘mediator
combinations’’ which can cause significant
activation and proliferation/differentiation
responses in the skin compartment are, for
example, TNF ? IL-17, IFNc ? TNF, and
IFNc ? IL-17 [1]. Enhanced pro-inflammatory
properties have also been described for the
combined action of IL-22, IL-17, TNF, and
IFNc both in the skin and synovial
compartment. The p40 unit shared by IL-12
and IL-23 is a fascinating therapeutic target as it
influences two important effector cytokines,
IFNc and IL-17, the production of which is
regulated by IL-12 and IL-23, respectively.
Ustekinumab (UST) is a monoclonal antibody
which targets the p40 subunit shared by IL-23
and IL-12.
THE ROLE OF IL-12/23
IN INFLAMMATORY IMMUNE
RESPONSES
The p40 b-chain can pair with the p35 or p19
subunit to form the heterodimeric cytokine IL-
12 or IL-23, respectively. IL-12 and IL-23 are
members of the IL-12 family along with IL-27
and IL-35 (for a review see [2] ). The p35 subunit
of IL-12 is expressed ubiquitously whereas p40
expression largely restricted to antigen
presenting cell (APC) types. Although p40
homodimers have been described for their
antagonistic action on IL-12/IL-23, this has
not been convincingly shown in the human
system. The p19 and p35 on their own are
biologically inactive. IL-12 and IL-23 each bind
to a two-subunit receptor complex. They share
the IL-12Rb1 receptor but differ regarding
signaling pathway activation by binding to the
high affinity IL12Rb2, which is highly expressed
on type 1 cells (including T helper (Th) cells
type 1 and ILC1) and IL-23R, respectively. IL-
23R is one of the susceptibility genes
highlighted by genome-wide association
studies for both psoriasis and psoriatic arthritis
(PsA) as is IL12B, which encodes for p40 [3]. IL-
23 and IL-12 can both activate molecules of the
same signaling pathways and these include
JAK2, TYK2, STAT1, STAT3, STAT4, and STAT5.
However, IL-12 predominantly signals via
STAT4 phosphorylation, whereas IL-23 has a
stronger impact on STAT3 pathway activation.
There is a positive feedback loop in that STAT3
pathway activators (e.g., IL-23, IL-6, OSM, IL-
22) can upregulate the cell surface expression of
IL-23R; similarly STAT4 activation leads directly
and indirectly via IFNc secretion on IL-12Rb2
expression [4]. Importantly high expression of
IL-12Rb2 is also influenced by IL-18 and by type
I IFNs, which are highly expressed in psoriatic
inflammation.
IL-12, which is mainly produced by
macrophages and dendritic cells (DC), is a
crucial molecule for polarization of CD4? cells
along the Th1 lineage [5, 6]. It is also well
described for its action on cytotoxic CD8? T
lymphocytes and natural killer (NK) cells which
ultimately can lead to their enhanced
cytotoxicity. By acting on NK, CTL, Th1, and
ILC type 1 the presence of IL-12 will lead to
production of IFNc. The action of IL-12, in
particular regarding IFNc production, can be
supported by co-stimulators and among the
soluble factors TNFa as well as IL-18 are known
for this action. IFNc and IL-12 act in a positive
feedback loop in a number of ways. IL-12
induced IFNc and IFNc primes APCs for IL-12
production. IFNc is a prototypic ‘‘priming’’
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signal which means it makes cells
(macrophages, DCs, keratinocytes) much more
susceptible to any ‘‘second’’ signal such as TNFa.
In the context of skin inflammation, and in
particular psoriasis, it is of interest that IL-12
can induce the expression of cutaneous
lymphocyte antigen (CLA) on lymphocytes [7,
8]. This homing receptor is responsible for
directing lymphocyte trafficking into the skin.
Regarding T cell differentiation, IL-12 also has
strong antagonist actions on Th2 pathway
polarization [9] and the class switch towards
immunoglobulin (Ig) E. IL-12 has also been
described for its inhibitory impact on retinoic
acid receptor-related orphan receptor-cT
(RORcT), a key transcription factor for Th17
polarization. As a result, IL-12 can act on
differentiating human Th17 cells to switch
them to more IFNc production.
Main Actions of Importance for Psoriasis
IL-12 is key for the production of INFc which is
one of the strongest activators of keratinocyte
proinflammatory responses (Fig. 1). IFNc
induces the production of CXCL10 in
keratinocytes, which attracts even more
CXCR3 ? IFNc producing T cells. Similar
mechanisms are in place on the level of the
synovium. The proinflammatory properties of
both IL-12 and IFNc can be enhanced by TNFa.
IL-12 can furthermore play a role in the homing
of lymphocytes into the skin by virtue of its
action on CLA expression.
IL-23 is also mainly produced by activated
APCs (macrophages, DCs) [10]. IL-23 was only
described a number of years after IL-12 and
many of the early studies which measured IL-
12p40 did not distinguish between IL-23 and IL-
12 functional effects. All initial data on IL-23
highlighted this cytokine as inducer of IFNc
production. Indeed, human IL-23 induces the
proliferation and the production of IFNc by
memory T cells. However, unlike IL-12 it does
not act on Th1 polarization and does not
support naı¨ve T cells to develop to IFNc
producers. Different from IL-12, IL-23 is
critical for activation, survival, and expansion
of type 17 cells [10–12]. RORcT positive T cells,
NKT cells and ILC which can produce IL-17 are
termed type 17 cells. IL-23 stabilizes IL-17
expression but, unlike IL-12’s action on Th1
cells, does not act as differentiation factor for
Th17 polarization. IL-23 induces a
proinflammatory signature that includes IL-17,
TNFa, CCL20, IL1R1 and IL-23R. By acting on
(1) IL-23R expression which increases the
cellular sensitivity to IL-23, (2) on CCL20, a
chemokine which directs the movement of
CCR6? IL-17 producers, and (3) IL-17
production, a strong positive feedback loop
supporting ‘‘type 17 inflammation’’ is created
which plays an important role in chronic
psoriatic inflammation. IL-1 and IL-23 act in
synergy to induce local tissue inflammation and
IL-23 increases the cellular sensitivity to IL-1 by
acting on its receptor expression.
Main Actions of Importance for Psoriasis
Actions of IL-23 will ultimately lead to IL-17
production and support the survival and via
CCL20 the recruitment of type 17 cells (Fig. 1).
Those cells also produce IL-22. Both IL-22 and
IL-17 directly activate keratinocytes but also
synovial cells. IL-17 and TNF show synergistic
proinflammatory functions. IL-17 and IL-22 are
responsible for high production of
antimicrobial peptides (including b defensins)
which play a chemotactic and proinflammatory
role in psoriasis pathogenesis. Furthermore, IL-
22 (and related IL-20 subfamily members) are
Rheumatol Ther (2015) 2:1–16 3
key to the changes seen in keratinocyte
differentiation and proliferation which are so
characteristic for the psoriatic phenotype.
MAIN FUNCTION OF IL-12/23P40
BLOCKADE IN PSORIASIS
This therapeutic intervention can act on many
different levels as highlighted above. Reducing the
proinflammatory actions of the effector cytokines
IFNc and IL-17/IL-22 seems key. However, there is
also some counter-regulation between type 1 and
type 17 cells. Depending to the ‘‘molecular’’
subtype of psoriasis or the disease to be treated,
breaking this counter regulatory balance could, to
some extent, lead to ‘‘weakening’’ of the anti-
inflammatoryactionof the inhibitor.Ontheother
hand, in theory, higher availability of p35 subunit
(although widely expressed) could lead to increase
in the regulatory IL-12 familymember IL-35which
is a p35/EBI3 heterodimer; however, this remains
to be shown.
Fig. 1 Schematic, simpliﬁed overview of IL-12/IL-23
dependent action on molecules involved in psoriatic
inﬂammation. Only positive/activating pathways are
depicted. Both IL-12 and IL-23 are produced by activated
APCs including macrophages. Upon receptor ligation,
these heterodimeric cytokines activate the Stat4/3
pathways ultimately resulting in upregulation of cell
surface receptors and secretion of cytokines. Of
importance, type 17 cells, which are dependent on IL-23
stimulation, express high levels of CCR6 which enables the
cell to follow a chemokine gradient build by CCL20 which
is produced by IL-17/IL-22 stimulated keratinocytes. Thus
type 17 cells will home into CCL20 rich tissues. On the
other hand, IL-12, via activation of Stat4, acts on
expression of the skin homing receptor CLA but also
CXCR3 which interacts with the chemokines CXCL9, 10,
11 which are all highly expressed by keratinocytes which
have been exposed to IFNs. IFNc is one of the strongest
priming signal for APC to induce the production of the
IL-12 family members IL-12 and IL-23. Negative regula-
tory feedback actions are not depicted in this ﬁgure.
However, there is signiﬁcant negative cross-regulation
between type 1 and type 17 cells. Blocking the p40 subunit
of both IL-12 and IL-23 could therefore result in
‘‘paradoxical’’ effects where this negative regulatory
inﬂuence plays an important role in disease pathology.
APC Antigen presenting cell, CLA Cutaneous lymphocyte
antigen, IFN Interferon, IL Interleukin
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IL12/23 Inhibitors in Other Dermatologic
Diseases
Sarcoidosis is a disease with high IL-12 activity.
Both the p40 subunit as well as the expression
of the high affinity IL-12Rb2 has been found
increased in this disease. While there are reports
on successful treatment of sarcoidosis with UST
there is also a case report suggesting a
paradoxical sarcoidosis promoting effect under
p40 inhibition, similar to what has been
reported for TNF blockade [13]. A recent study
on skin and lung sarcoidosis patients suggests
that blockage of TNF may result in more
favorable therapeutic effects for the skin than
that of p40 blockade for the time period
observed [14]. Case reports suggest that UST
could be of benefit in therapy resistant
Pyoderma gangrenosum [15, 16], hidradenitis
suppurativa [17, 18], SAPHO syndrome [19],
and pityriasis rubra pilaris [20–23].
CLINICAL STUDIES IN PSORIASIS
In January 2009, UST (CNTO 1275, Stelara;
Janssen Cilag) was granted marketing
authorization by the European Commission
for the treatment of moderate to severe
chronic plaque psoriasis in adults who failed
to respond to, who have a contraindication to
or who are intolerant of systemic oral
immunosuppressants. Unlike the other
biological anti-psoriatic agents already brought
to market, which all targeted TNFa, UST was the
first-in-class anti-IL agent for psoriasis,
representing an important milestone in
rational drug design. UST is a fully human
IgG1j monoclonal antibody that inhibits IL-12
and IL-23 activity by binding with high affinity
and specificity to their shared p40 subunit. IL-
12/23 bioactivity is thus inhibited by
preventing their binding to IL-12 receptor b1
(IL-12Rb1) on the surface of immune cells.
Phase I and II Clinical Trials
UST’s therapeutic potential was apparent in early
phase I studies, with reductions in lesional gene
expression of IL-12p40, IL-23p19 and other
inflammatory cytokines as early as two weeks
post treatment [24–26]. The drug was well
tolerated and appeared to have low
immunogenic potential. In some patients, a
single intravenous or subcutaneous dose
resulted in a rapid and marked clinical response
that was sustained for 16–24 weeks. In an initial
phase II randomized trial [27], 320 patients were
allocated to one of five groups, receiving placebo
or one of four doses of UST (45 or 90 mg once
only, or 45 or 90 mg weekly for 4 weeks). At week
16, patients treated with UST with a physician’s
global assessment (PGA) of three or more
received an additional injection of their initial
dose. At week 20, those in the placebo arm
received a single 90 mg dose. The primary
endpoint of Psoriasis Area and Severity Index
(PASI) 75 response at week 12 showed statistical
significance for all active treatment groups
(51.6% for 45 mg once only, 59.4% for 90 mg
once only, 67.2% for four doses of 45 mg weekly,
81.3% for four doses of 90 mg weekly), compared
with 1.6% in the placebo group. Clinical
responses were maintained out to week 24
before deterioration and were supported by
substantial improvements in the Dermatology
Life Quality Index (DLQI). Serious adverse events
were not statistically higher in any group.
Phase III Clinical Trials
Following on from the promise shown in the
phase II study, the safety and efficacy of UST
were further assessed in three large phase III
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clinical trials involving 2,899 adult patients
with moderate to severe psoriasis (PASI[12,
PGA C3 or 10% body surface area involvement)
of at least 6 months duration and who were
candidates for systemic immunosuppression
or phototherapy. Run in parallel, both
PHOENIX I (ClinicalTrials.gov #NCT00267969)
[28] and PHOENIX II (ClinicalTrials.gov
#NCT00307437) [29] were multicenter,
randomized, double-blind, placebo-controlled
trials with similar objectives and methods and
a primary endpoint of PASI 75 response from
baseline at week 12. The same primary endpoint
was selected for the third, the ACCEPT
(ClinicalTrials.gov #NCT00454584) trial, but
differed in that it compared UST with
etanercept in place of placebo [30].
PHOENIX I, a 76 week study, involved 766
patients, 53% of which were either non-
responsive to, intolerant of or had a
contraindication to other systemic therapy
[28]. Participants were initially randomized
(1:1:1) to placebo or active treatment with UST
at either 45 mg or 90 mg subcutaneously at
week 0, 4, and then every 12 weeks thereafter.
Baseline randomization was stratified by study
site, weight (B90 or[90 mg) and the number of
systemic therapies to which the patient had had
an inadequate response, intolerance or
contraindication (\3 or C3).
Patients in the active treatment group who
achieved a PASI 75 response at both weeks 28
and 40 were re-randomized at week 40 to
maintenance UST (same dose as initial stage)
or withdrawal from treatment (placebo
administered) until loss of response.
Randomization at week 40 was also based on
study site and patient weight. Patients in this
group who had achieved a partial (PASI 50–PASI
74) response at week 40 were adjusted to a
dosing interval of every 8 weeks. Patients
randomized to receive placebo at week 0 and
week 4 crossed over to receive UST (45 or 90 mg)
at weeks 12 and 16, followed by dosing every
12 weeks thereafter. This study design allowed
not only comparison of UST against placebo,
but also long-term efficacy, duration of
therapeutic effect after drug withdrawal and
possible dose escalation in partial responders
[28].
At the primary endpoint (week 12), 67.1%
of those receiving the 45 mg dose and 66.4%
of those receiving 90 mg achieved PASI 75,
compared to 3.1% of the placebo group
(P\0.0001). Improvement was rapid, with
many in the active treatment groups,
regardless of dose, achieving PASI 50 by
week 2. Maximum efficacy was observed at
week 24 for both dosing regimens (76.1 and
85.0% PASI 75 response for 45 and 90 mg,
respectively), with similar findings in the
group initially assigned to placebo after
crossing over to active treatment at week 12
[28].
After re-randomization at week 40, either
maintenance therapy or withdrawal,
preservation of PASI 75 was significantly
greater in those receiving continuous UST
therapy (84% at week 76) compared with the
treatment withdrawal group (19% at week 76).
In the latter, PASI scores began to deteriorate by
week 44 (16 weeks after last injection), and
accelerated after week 52. Withdrawn patients
were re-treated with their initial dose after their
PASI 50 response was lost. A total of 195
patients needed to restart therapy and 85.6%
regained their PASI 75 after 12 weeks of re-
treatment [28].
Expanding on the initial PHOENIX I trial
data reported at week 76, all patients were
subsequently followed to week 244 (5 years) to
assess longer-term safety and efficacy [31, 32].
Overall, 68.7% (n = 517) of the initial overall
population of 753 (who had received at least
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one dose of UST in PHOENIX I) were evaluated.
Initial clinical responses were generally
maintained through week 244 (PASI 75: 63.4
and 72.0%; PASI 90: 39.7 and 49.0%; PASI 100:
21.6 and 26.4% for patients receiving 45 or
90 mg, respectively) [31]. At week 264, analysis
of 8998 patient years of follow-up demonstrated
event rates (per 100 patient years; 45 and 90 mg,
respectively) for all adverse events (242.6,
225.3), serious adverse events (7.0, 7.2), serious
infections (0.98, 1.19), non-melanoma skin
cancers, or NMSCs (0.56, 0.36), other
malignancies (0.59, 0.61), and major adverse
cardiovascular events, or MACE (0.56, 0.36),
that were comparable between the two dosing
groups. No increasing trend in any adverse
events was seen over time, and the rates of
overall mortality and other malignancies were
comparable with the general population of the
United States [32].
Nail involvement may be present in up to
80% of patients with psoriatic disease and is
notoriously difficult to treat, leading to high
psychosocial embarrassment [33] and in severe
cases, functional limitation [34]. Improvements
in fingernail psoriasis were assessed in the
PHOENIX I cohort using the Nail Psoriasis
Severity Index (NAPSI) on a target fingernail in
addition to a nail PGA and assessment of the
mean number of nails involved [35]. Of the 766
randomized, 545 had nail psoriasis. By week 24,
the percentage improvement in NAPSI from
baseline was 46.5 and 48.7% for UST 45 and
90 mg, respectively. Improvements in the less
sensitive nail PGA scores were generally not
observed in the overall nail psoriasis cohort at
week 12; however, substantial improvements
were noted at week 24, with the majority of
patients with a PGA C3 at baseline achieving
improvement by at least one point. In the 45
and 90 mg groups, 77.0 and 75.0%, respectively,
of patients with moderate nail disease (PGA 3)
improved to mild (PGA 2) or clear (PGA 1) by
week 24.
The second large phase III clinical trial,
PHOENIX II, recruited 1,230 patients and 61%
were either non-responsive to, intolerant of or
had a contraindication to other systemic
therapy [29]. Like PHOENIX I, patients were
randomized to one of three arms; 45 mg or
90 mg subcutaneously at week 0, 4 and every
12 weeks, or placebo at weeks 0 and 4 and then
crossover to active therapy (randomized 1:1 to
either 45 or 90 mg) at week 12 (with loading
doses at week 12 and 16, followed by injections
every 12 weeks thereafter). At week 28, patients
were deemed responders (PASI 75 response
achieved), partial responders (PASI 50–74) or
non-responders (PASI\50). Responders
continued treatment at the same dose every
12 weeks, non-responders discontinued
therapy, and partial responders were re-
randomized to either continue their current
regimen or reduce their dosing interval to every
8 weeks. Stratification was as described for
PHOENIX I. The partial responder group
permitted analysis of the number of visits
between weeks 28 and 52 where PASI 75 was
achieved for the two different dosing schedules.
At week 12 (primary endpoint), 66.7% of
patients receiving UST 45 mg and 75.7% of
patients receiving 90 mg every 12 weeks
achieved PASI 75 (P\0.0001), compared with
3.7% of participant receiving placebo.
Maximum efficacy was seen around week 20
for both doses (PASI 75 in 74.9 and 83.5% for 45
and 90 mg, respectively), with similar outcomes
seen in the placebo group after crossing over to
active therapy. In those who achieved PASI 75
by week 28, the improvement was maintained
until the end of the study (week 52). In all, the
median clinical response at the end of the study
was PASI 95 for those in the 45 mg group and
PASI 96 for those in the 90 mg group [29].
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Partial responders accounted for 22.7% of
those receiving 45 mg every 12 weeks, and
15.8% of those receiving 90 mg. At baseline,
compared to responders, these individuals were
of a greater body weight, had more severe PGA
scores, a longer duration of psoriasis, a greater
incidence of PsA, a higher failure rate with
previous systemic immunosuppressants and
lower serum drug levels at week 28. For those
receiving 90 mg, a reduction in the dosing
interval from 12 to 8 weeks did equate to a
greater number of visits where a PASI 75
response was achieved, but this was not the
case for those receiving 45 mg [29].
In terms of safety, both PHOENIX I and II
reported similar outcomes during the placebo-
controlled phase. Adverse events occurred in
278 (54.5%) of the 510 patients receiving UST in
PHOENIX I [28] and 414 (50.5%) of 820 patients
in PHOENIX II [29]. This is compared with 48.2
and 49.8% in their respective placebo groups.
Serious adverse events occurred in similar
proportions in both trials and with similar low
frequencies between the UST and placebo
treated arms (1.2% UST vs. 0.8% placebo in
PHOENIX I; 1.6% UST vs. 2.0% placebo in
PHOENIX II). In PHOENIX I, the pattern of
adverse events was much the same in the
placebo crossover and randomized withdrawal
phases as it was in the placebo-controlled phase
[28]. Rates of antibody formation to UST were
found in 5.1% of patients by the end of week 76
(PHOENIX I) and 5.4% of patients by the end of
week 52 (PHOENIX II), and in both trials, these
were mostly of low titer.
The ACCEPT phase III clinical trial differed
from the PHOENIX trials in that the safety
and efficacy of UST were compared with an
active comparator (etanercept) rather than
placebo [30]. In this 64 week trial, 903 patients
were randomized (3:5:5 ratio) to receive
subcutaneous injections of UST (45 or 90 mg)
at weeks 0 and 4, or etanercept (50 mg) twice
weekly for 12 weeks. Randomization was
stratified according to study site and baseline
weight (\90 or C90 mg). Patients were aware of
their treatment, but study assessors remained
blinded. At week 12, patients in the etanercept
group who did not respond (classified as
moderate, marked or severe psoriasis on the
PGA) were given 90 mg UST at weeks 16 and 20,
and those who did not respond in the UST
group were given one further additional dose of
UST at week 16. For those who did respond
(classified as clear, minimal, or mild) at week 12,
treatment was withdrawn. If psoriasis recurred
and was graded moderate, marked or severe,
patients were retreated with UST, regardless of
initial therapy.
At week 12, 67.5 and 73.8% of patients
receiving 45 and 90 mg UST respectively
achieved PASI 75, compared with 56.8% of
those receiving etanercept (P = 0.01 and
P\0.001, respectively), and the time to
improvement was more rapid in those treated
with UST. PASI 90 responses were achieved in
36.4% of patients receiving 45 mg UST, 44.7%
of patients receiving 90 mg UST and 23.1% of
patients receiving etanercept (P\0.001 for
both). Amongst those patients who were
deemed non-responders to etanercept, 48.9%
achieved PASI 75 and 23.4% achieved PASI 90
12 weeks after crossing over to UST. For those
who were graded as responders at week 12 and
had therapy withdrawn, the median time to
recurrence was 14.4 weeks (45 mg UST),
18.1 weeks (90 mg UST) or 7.3 weeks
(etanercept). Of the 633 patients who were
retreated after re-emergence of moderate to
severe psoriasis, 534 were classed as having
mild, minimal or no psoriasis within 12 weeks
[30].
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Adverse events occurred with similar
frequency across all treatment groups, with at
least one event in 70.0% of etanercept-treated
participants, 66.0% in the 45 mg UST group and
69.2% in those receiving 90 mg UST. Most
adverse events were classed as minor, with
only 12 patients (4 in each group) from the
903 recruited having a major event. Overall,
discontinuation of therapy was necessary in
similar proportions, ranging from 1.2 to 2.3%. A
noticeable discrepancy was seen in injection site
reactions (24.8% of patients who received
etanercept as compared with 4.3% (45 mg) and
3.7% (90 mg) of patients receiving UST),
although it is worth acknowledging the higher
number of injections necessitated by the dosing
schedule of the etanercept arm. Through to
week 12, infections occurred at comparable
rates in the three treatment groups (29.1, 30.6,
and 29.7% in the groups that received
etanercept, 45 mg UST, and 90 mg UST,
respectively) and this was relatively consistent
to the end of the trial. NMSCs occurred only in
patients treated with UST but at low numbers
(three by week 12 and a further nine by week
64). Quality of life indices were not recorded in
the ACCEPT trial [30].
Several other smaller phase III clinical trials
have assessed the safety and efficacy of UST in
non-western populations and found similar
clinical responses. In the PEARL trial, 121
Taiwanese and Korean patients with moderate-
to-severe psoriasis were enrolled into a 36 week,
multicenter, double-blind, placebo-controlled
trial to receive UST 45 mg at week 0, 4 and 16,
or placebo at week 0 and 4, followed by UST at
week 12 and 16 [36]. At the primary endpoint
(week 12), PASI 75 was achieved by 67.2% in the
UST-treated group, and 5.0% in the placebo arm
(P\0.001). Efficacy was maintained through to
week 28 in the UST group. Adverse events were
similar between the groups, with exception of
abnormal hepatic function, which was related
to concomitant isoniazid treatment for latent
tuberculosis. No deaths, malignancies, or MACE
were reported. An identical study design was
employed in a 72 week phase II/III clinical trial
involving 158 Japanese patients, with the
addition of 90 mg UST arm [37]. At week 12,
59.4% and 67.7% of UST 45 mg and 90 mg
treated patients achieved PASI 75, compared
with 6.5% in the placebo group (P\0.0001). By
week 12, rates of infections were comparable
amongst the groups (UST 45 mg, 20.3%; 90 mg,
24.2%; placebo, 18.8%), and only single cases of
serious infections and non-cutaneous
malignancies were recorded, both occurring in
the 90 mg ustekinumab group. There were no
reports of NMSC. Through to week 72, similar
rates and types of adverse reactions and serious
adverse were reported between the 45 and
90 mg ustekinumab-treated groups.
Factors Influencing Clinical Response
to UST
HLA-Cw06 has long been established as the
most potent psoriasis susceptibility gene.
However, latterly, observations have suggested
that this genetic polymorphism could serve as a
pharmacogenetic marker to predict clinical
response to immunomodulatory agents
including UST [38]. Talamonti et al. [39]
observed a statistically significant increased
response to UST in HLA-Cw06–positive
patients (PASI 75 response at week 12: 96.4 vs.
65.2% in HLA-Cw06–negative individuals). The
time to response was also faster, with 89.3% of
HLA-Cw06–positive patients reaching PASI 50
at week 4 (after one single dose) compared to
60.9% of HAL-Cw06–negative patients. No
significant association was found between
clinical response and the other psoriatic
genetic markers studied (TNFAIP3rs610604
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polymorphism and LCE3B/3C gene deletion)
[39]. Genetic susceptibility to psoriasis can vary
between races, although Chiu et al. [40]
replicated the Italian study in Chinese patients
with psoriasis.
In addition to genetic factors, obesity has
been recognized as an important factor related
to both the incidence and severity of psoriasis
[41]. Obesity can induce an overproduction of
multiple proinflammatory cytokines in adipose
tissue, including TNFa, IL-6 and IL-8, all of
which are implemented in the pathogenesis of
psoriasis [42]. Lebwohl et al. [43] evaluated the
effect of weight on response to UST in patients
enrolled into the PHOENIX I and II trials and
found that those with a body mass greater than
100 kg had a reduced efficacy to UST. The
proportion of patients with a body
mass B100 kg achieving PASI 75 was 76.9%,
compared to 54.6% in those weighing[100 kg
at the 45 mg dose, and 80.8% (B100 kg)
compared to 74.2% ([100 kg) at the 90 mg
dose. Serum drug concentrations were also
affected by weight, and together these findings
provided the rationale for the higher dose
subsequently licensed for patients weighing
more than 100 kg [43].
Quality of Life Response
In PHOENIX I, more than 97% of patients had a
score of 1 or more on the DLQI at baseline, and
the average score was greater than 10 out of a
possible maximum of 30, indicating a
significant impact on patients’ quality of life
[44]. Significantly greater proportions of
patients receiving UST 45 mg and 90 mg
achieved a normalization of DLQI (B1)
compared with placebo (53.2, 52.4, 6.0%,
respectively, both p\0.001) at week 12. The
SF-36 questionnaire revealed similarly
impressive results for both the physical
(45 mg, 23.1%; 90 mg, 33.7%; placebo, 15.6%)
and mental (45 mg, 25.5%; 90 mg, 31.3%;
placebo, 14.8%) component scores by week 12
(P\0.001). The greatest improvements were
found in the bodily pain and social functioning
domains. These quality of life improvements
were sustained with maintenance UST therapy
at one year.
In the PHOENIX II trial, the Hospital and
Anxiety Depression Scale (HADS) replaced the
SF-36, alongside the DLQI [45]. At baseline, a
high psychological impact of disease was
apparent, with 40.3% in the group receiving
UST 45 mg, and 26.7% receiving 90 mg,
reporting symptoms of anxiety and
depression, and 54.6% reporting a DLQI C10.
By week 12, the absolute mean (±SD) reduction
in DLQI was by 9.3 points (±7.1) in the 45 mg
group, 10.0 (±6.7) points in the 90 mg group,
compared with -0.5 (±5.7) in the placebo arm.
The proportion of patients with baseline
symptoms of mild to severe anxiety (as
assessed by HADS-A) decreased from 38.2 to
25.7% by week 12 in the UST 45 mg group and
from 41.0 to 27.1% in the UST 90 mg group
(P\0.001 vs. placebo), representing a
combined relative reduction of 34% from
baseline (compared with a 1.4% increase in
the placebo group). The prevalence of baseline
symptoms of mild to moderate depression (as
assessed by HADS-D) decreased from 24.7 to
12.8% by week 12 in the UST 45 mg group and
from 31.1 to 12.5% in the 90 mg group
(P\0.001 vs. placebo), representing a relative
reduction of 55% from baseline (compared with
an increase of 10% in the placebo group).
Sexual difficulties were specifically analyzed
from the DLQI data collated in both PHOENIX I
and II [46]. Impaired sexual function was
recorded if any patient scored ‘very much’ or
‘a lot’ for question 9 of the DLQI. 27.1% of
women and 20.8% of men reported impaired
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sexual function at baseline, and this was
significantly associated with increased psoriasis
severity. At week 12, the overall proportion of
patients with sexual difficulties decreased from
22.6 to 2.7%, compared to no change in the
placebo arm (P\0.001). Patients with a greater
mean improvement in PASI score experienced a
greater reduction in sexual difficulties caused by
psoriasis.
CLINICAL STUDIES IN PSA
For UST, in PsA, the main phase III studies are
PSUMMIT-1 (ClinicalTrials.gov #NCT01009086)
[47] and PSUMMIT-2 (ClinicalTrials.gov
#NCT01077362) [48]. In PSUMMIT-1, 615
patients with active PsA, stratified by weight
and methotrexate (MTX) use, were randomized
to placebo, UST 45 mg or UST 90 mg (injections
were given at weeks 0, 4 and every 12 weeks
thereafter. At week 12 patients with an
inadequate response (\5% improvement in
tender and swollen joint counts) could
escalate (placebo to UST 45 mg, UST 45 mg to
UST 90 mg, but no escalation if the patient was
already taking UST 90 mg). The primary
outcome measure was the American College of
Rheumatology (ACR) 20 rate at week 24
(Table 1). Significant differences between
groups, in favor of UST, were seen (placebo
22.8%, UST 45 mg 42.4%, UST 90 mg 49.5%). As
with TNF inhibitors (TNFi), the concomitant
use of MTX did not appear to make any
difference to the efficacy of this drug
(combined UST groups: ACR20 with MTX
44.5%, without 47.5%). The kinetics of the
ACR response suggested that a peak was reached
at week 28. As for the other manifestations of
psoriatic disease, skin, dactylitis and enthesitis
showed significant improvement with both
doses of UST and, in cases with spondylitis,
significant improvement in Bath Ankylosing
Spondylitis Disease Activity Index (BASDAI)
scores. At week 16 adverse events were similar
between placebo and active drug groups with
nasopharyngitis, upper respiratory infections
and headache the main adverse events with
UST. Over 52 weeks, 4 serious infections were
reported. Of note, three major cardiovascular
events occurred in the UST groups in the first
30 weeks of treatment.
Patients in PSUMMIT-1 were TNFi naı¨ve.
PSUMMIT-2 addressed the issue of previous
TNFi exposure. Although a similar design was
employed (same criteria for active disease,
randomization and early escape, stratification
for weight and MTX use) just over half of the 300
patients recruited had prior TNFi exposure. Of
these TNFi experienced patients the majority had
used more than one agent and 70% had
discontinued the drug because of inadequate
response. In PSUMMIT-2 the primary end-point
of superiority over placebo at week 24 was
reached despite the more challenging patient
population and the smaller sample size (Table 1).
As expected response rates in those patients who
were TNFi experienced were inferior to TNFi-
naı¨ve patients. Of interest, results were
independent of MTX usage and, generally,
weight, although response was not as good in
patients over 100 kg in the UST 90 mg group. As
with PSUMMIT-1 improvement was seen in skin,
enthesitis, BASDAI in patients with spinal
inflammation, fatigue, and function but not for
dactylitis. No major MACE events were seen up to
week 16 but up to week 60 the myocardial
infarction rate was 0.74/100 patient years.
In order to achieve a sufficient sample size,
structural progression analyses were pre-
specified for a pooled analysis of PSUMMIT-1
and PSUMMIT-2 patients [49]. Thus, 927
patients were available with a missing data
rate of about 10% overall (there were more
patients who were TNFi experienced in placebo
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arm with missing data than in other groups). A
significant reduction in radiographic
progression at 24 weeks was found with
changes in the modified Sharp van der Heijde
score (mSvdH) of 1 in the placebo arm and 0.4
in both UST arms. Median scores for change
were, however, low over the whole cohort. At
24 weeks the percentage of patients with a
radiographic change score which was less than
the smallest detectable difference was 83.8% in
the placebo arm, 91.7% in the UST 45 mg arm
and 91.9% in the UST 90 mg arm. Over the
52 week observation period these rates of
progression remained stable. The mSvdH score
does not measure new bone formation, so no
information was available on this important
radiographic feature. Cases with osteolysis and
‘pencil in cup’ were noted separately and were
also infrequent and stable over 52 weeks.
To date, the only other available data on
UST comes from meeting abstracts. Safety data
from pooled psoriasis and PsA studies were
reported at the ACR meeting in 2013 [50] and
2014 [51]. No worrying signals for serious
infection or malignancy were found but
MACE events once more appeared higher in
the UST treated patients, although confidence
intervals (CI) did overlap with the placebo rate
(placebo: rate of events per 100 patient years of
exposure (95% CI): 0 (0–1.69); UST 1.23
(1.40–2.87)). In 2014, pooled data over a two-
year period did not support an increase in
MACE events in either dose (45 or 90 mg) of
UST [52]. Of interest, and as a complement to
the data in the PSUMMIT studies on patients
with spondylitis, Poddubnyy et al. [53]
reported a small, open-label, proof of concept
study of UST in ankylosing spondylitis. In this
study, 20 patients with AS were given three
doses of UST at weeks 0, 4, and 16 and
assessments were made at week 24.
Significant improvements in the traditional
AS outcome measures were seen with 65% of
patients achieving an Assessment of
SpondyloArthritis international Society (ASAS)
40 response rate. Unlike with TNFi drugs, no
change in CRP was seen overall, but the CRP
was significantly reduced in the responders. In
2014, in abstract format, concomitant
reduction in inflammation identified on
magnetic resonance imaging was also
demonstrated in this cohort [54].
DISCUSSION
UST is a new class of drug specifically targeting
the IL-12/23 axis and is effective in psoriasis and
PsA. What is the likely use of this drug in
clinical practice? It is worth considering the
current treatment algorithms in use in this
Table 1 ACR20 rates for ustekinumab in phase III studies
PSUMMIT-1 PSUMMIT-2
Week 12* Week 24 Week 24
ACR20 ACR20 ACR50 ACR70 ACR20 ACR50 ACR70 ACR20 (TNFIR)
Placebo 21 23 9 2 23 7 3 15
UST45 mg 41 42 25 12 44 18 7 37
UST90 mg 41 50 28 14 44 23 9 35
All ﬁgures are (rounded) percentages
ACR American College of Rheumatology
* Taken from ﬁgure 2A in McInnes et al. [47]
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disease. Psoriasis and PsA will be considered
separately and then as a combined approach.
From the data available UST is a valuable
addition to psoriasis treatment, providing a
potent biologic alternative to the TNFi class of
drugs. The place of UST is similar to TNFi and the
decision to start UST as opposed to TNFi may
depend on such factors as contraindications to
TNFi, cost, and patient preference, given the
alternative dosing schedules of this drug. There
are as yet no data on the safety profile of UST with
ultraviolet therapy but it might be assumed that
their safety profile would be favorable when
compared to drugs such as TNFi.
When a new drug works well for psoriasis the
most important question concerns its efficacy
against the articular part of the disease. From a
patient point of view, a drug that works against
all aspects of the disease is ideal, and if topical
therapy can be avoided, so much the better.
TNF inhibitors fulfil this role well and remain
the yardstick by which other drugs are
measured. However, not all drugs active
against psoriasis work for the joints. The prime
example was efaluzimab, now withdrawn,
which may have induced cases of PsA in
patients with psoriasis [55]. UST is clearly
effective in PsA: not only the articular
manifestations but those other features so
characteristic of the disease: enthesitis,
dactylitis, and spondylitis. At this moment
TNFi drugs set the benchmark of response in
PsA and, on the evidence from the PSUMMIT
trials UST is probably not quite as efficacious as
TNFi for the articular manifestations. However,
only head-to-head data will be able to confirm
this observation given the possible disparity of
patient populations across the studies.
Nevertheless, UST, like TNFi is effective for all
aspects of the disease, skin and musculoskeletal
and, from a patient point of view this is an
attractive feature.
The kinetics of response may be of some
concern. If a rapid response of skin and joints is
required then the physician is more likely to
recommend a TNFi, or one of the IL-17
inhibitors. On the other hand, if there has
been TNFi failure, then UST may be an
attractive option, given the results of the
PSUMMIT-2 study. More data is needed on the
response to UST according to primary or
secondary non-response to TNFi—it is likely
these data are available from the PSUMMIT-2
study and will no doubt appear in due course.
The 52 week results also suggest that alternative
dosing schedules may be required for articular
and other musculoskeletal manifestations,
possibly with a shorter dosing interval.
UST will have a place in treatment when
TNFi are contra-indicated (currently with a
history of demyelinating disorder, active
tuberculosis, or a recent malignancy) although
it must be emphasized that we still do not know
the safety of UST in these situations. A doubt
still remains about MACE events with UST and
only long term surveillance using registry data
will be able to illuminate this and other safety
concerns.
Should UST be co-prescribed with MTX? The
studies so far do not indicate any enhancement
of efficacy with MTX use but, as with TNFi,
MTX may prolong the effective period of this
drug, although the rate of antibody formation
to UST seems low. However, many patients find
the higher doses of MTX unacceptable so it
would be prudent to use a low maintenance
dose of 10–15 mg.
CONCLUSION
UST provides another weapon in the physicians
armory, with a new target. Cost issues will be
equivalent to TNFi and other biologics so its
place in the treatment algorithm of psoriasis
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and PsA will evolve over time and with
continued use. The different mode of action
will offer a treatment alternative to TNFi failures
but the rather slow onset of action may be a
problem for some patients and their physicians.
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